Diabetologie und Stoffwechsel 2021; 16(S 01): S4
DOI: 10.1055/s-0041-1727302
01. Klinische Diabetologie

Clinical characteristics, treatment patterns and persistence in patients with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry

H Jung
1   Lilly Deutschland GmbH, Global Patient Safety - Medical Diabetes, Bad Homburg, Germany
,
SR Tittel
2   Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm / Deutsches Zentrum für Diabetesforschung (DZD), Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Ulm / München-Neuherberg, Germany
,
N Schloot
3   Lilly Deutschland GmbH, Global Development – Medical Diabetes, Bad Homburg, Germany
,
E Heitmann
4   Lilly Deutschland GmbH, Medizinsche Abteilung - Diabetes, Bad Homburg, Germany
,
T Otto
5   Lilly Deutschland GmbH, Gesundheitsökonomie, Bad Homburg, Germany
,
J Lebrec
6   HaaPACS GmbH, Statistik, Schriesheim, Germany
,
M Hummel
7   Diabetologische Schwerpunktpraxis / Forschergruppe Diabetes der TUM, Medizin, Rosenheim / München, Germany
,
M Pavel
8   Universitätsklinikum Erlangen, Medizinische Klinik 1, Erlangen, Germany
,
M Naudorf
9   Diabeteszentrum Lindlar, Praxis Michael Naudorf, Medizin, Lindlar, Germany
,
S Lanzinger
2   Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm / Deutsches Zentrum für Diabetesforschung (DZD), Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Ulm / München-Neuherberg, Germany
› Author Affiliations
› Further Information
Also available at
 

Background This retrospective analysis evaluates the clinical characteristics, treatment patterns and GLP-1RA persistence in patients with T2 D initiating their first GLP-1RA.

Methods Analysis of the multicentre DPV registry identified adult patients with T2 D initiating GLP-1RA therapy between 2007 and June 2020. The population was stratified by anti-diabetes therapy at time of GLP-1RA initiation into following subgroups: oral antidiabetic drugs (OAD), insulin ± OAD, or lifestyle modification (LM). GLP-1RA treatment persistence (overall and by baseline anti-diabetes treatment) in patients with ≥12-months follow-up was determined by Kaplan-Meier analysis.

Results In total, 15,111 patients with T2 D initiating a GLP-1RA therapy (55 % males) were identified. The baseline characteristics include median [interquartile range (IQR)] age (58.7 [50.6-66.7] years), diabetes duration (8.5 [3.6-14.7] years), BMI (36 [31.7-41.3] kg / m2) and HbA1c (8.2 [7.1-9.8] %). Subgroup analysis by baseline therapy (OAD:42 %, insulin ± OAD:50 %, LM:7 %) showed similar age and BMI while HbA1c varied (OAD:7.8 [6.9-9.4] %, insulin ± OAD:8.5 [7.4-10.1] %, LM:7.2 [6.4-8.4] %). The overall median [IQR] GLP-1RA persistence in eligible patients (n = 5,189) was 11 [0-51] months, with patients reaching a median HbA1c of 7.5 [6.6-8.7] % at discontinuation. Across subgroups, GLP-1RA persistence was OAD:12 [0-52] months (n = 2,453), insulin ± OAD:11 [0-54] months (n = 2,204), and LM:7 [0-36] months (n = 532), reaching a median HbA1c of 7.3 [6.4-8.5] % (OAD; n = 1,155), 7.8 [6.9-9.0] % (insulin ± OAD; n = 1,010), and 7.3 [6.4-8.2] % (LM; n = 261).

Conclusions Real-world DPV registry data revealed 92 % of patients with T2 D initiating a GLP-1RA added it to an OAD or insulin ± OAD treatment regimen, and 50 % showed a GLP-1RA persistence of > 11 months.



Publication History

Article published online:
06 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany